The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma

Basem Magdy William, Navneeth Rao Bongu, Martin Bast, Robert Gregory Bociek, Philip Jay Bierman, Julie Marie Vose, James Olen Armitage

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Background: Serum lactate dehydrogenase is a non-specific marker for lymphoma whose prognostic significance is well established for both indolent and aggressive lymphomas at the time of diagnosis. The performance characteristics of this enzyme in predicting relapse in patients with diffuse large B-cell lymphoma has not been well studied. Methods: This study compared serum lactate dehydrogenase levels in 27 patients with diffuse large B-cell lymphoma who relapsed after sustaining a complete response versus 87 patients who did not relapse. For relapsed patients, the serum lactate dehydrogenase level at relapse was compared with the level three months before (considered baseline). For non-relapsed patients, the last two levels during follow-up were compared. For statistical analysis the T-test was used to compare differences in mean values between groups. The sensitivity, specificity, positive and negative predictive values for serum lactate dehydrogenase in detecting relapse compared to confirmatory imaging were calculated. Results: At relapse, only 33% patients had increases in serum lactate dehydrogenase above the upper limit of normal. The mean increase was 1.2-fold above the upper limit of normal for relapsed vs. 0.83 for those who did not relapse (p-value = 0.59). The mean increase in serum lactate dehydrogenase, from baseline, was 1.1-fold in non-relapsed vs. 1.3 in relapsed patients (p-value = 0.3). The likelihood ratio of relapse was 4.65 for patients who had 1.5-fold increases in serum lactate dehydrogenase above baseline (p-value = 0.03). The sensitivity, specificity, positive and negative predictive values of 1.5-fold increases for detecting relapse, compared to clinical and imaging findings were 0.18, 0.95, 0.55, and 0.79, respectively. Conclusion: A 1.5-fold increase in serum lactate dehydrogenase, over a period of 3 months, is associated with increased likelihood of relapse from diffuse large B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)189-191
Number of pages3
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume35
Issue number3
DOIs
StatePublished - May 2013

Keywords

  • Antineoplastic agents
  • Diffuse
  • Follow-up studies
  • L-Lactate dehydrogenase
  • Large B-Cell
  • Lymphoma
  • Non-Hodgkin

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this